Title |
Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted
|
---|---|
Published in |
Drug Design, Development and Therapy, March 2012
|
DOI | 10.2147/dddt.s29916 |
Pubmed ID | |
Authors |
Olivier Lambert, Dirk Bandilla, Rupa Iyer, Leonore Witchey-Lakshmanan, Nagesh Palepu |
Abstract |
Epoprostenol, used for the treatment of pulmonary arterial hypertension (PAH), has a number of limitations related to its short half-life in aqueous solution. The aim of this study was to evaluate the stability and microbiological properties of a new formulation, namely epoprostenol sodium with arginine and mannitol excipients (epoprostenol AM; Veletri®; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland). |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 4% |
Unknown | 22 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 6 | 26% |
Researcher | 4 | 17% |
Student > Ph. D. Student | 3 | 13% |
Student > Bachelor | 2 | 9% |
Student > Doctoral Student | 1 | 4% |
Other | 1 | 4% |
Unknown | 6 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 7 | 30% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 26% |
Agricultural and Biological Sciences | 1 | 4% |
Biochemistry, Genetics and Molecular Biology | 1 | 4% |
Economics, Econometrics and Finance | 1 | 4% |
Other | 1 | 4% |
Unknown | 6 | 26% |